Could cutting-edge treatments for select cancers be steered into action against autoimmune disorders and infectious diseases?

The cancer treatments, called CAR-T therapies, involve supercharging immune cells and directing them to attack malignant cells. Only two have been approved so far, and only for certain leukemias and lymphomas. But as scientists and companies seek to expand the types of cancer CAR-Ts target, other researchers are experimenting with adapting them to a host of diseases beyond cancer.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy